New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll, commissioned by ImmunityBio, Inc. (NASDAQ: IBRX), has shed light on…
enGene Reports Updated LEGEND Phase 2 Data Showing 62% Complete Response Rate at Six Months for Detalimogene Voraplasmid in BCG-Unresponsive NMIBC enGene Holdings Inc. (Nasdaq: ENGN) (“enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced updated preliminary…
Revvity Launches Next-Generation Somatic Cancer Reference Standards in Collaboration with MDIC and NIST Revvity, Inc. today announced the release of its new, highly characterized Mimix™ Geni™ somatic cancer reference standards, developed in collaboration with the Medical Device Innovation Consortium (MDIC)…
Kardigan Showcases Positive Phase 2 Data for Ataciguat in Moderate Calcific Aortic Valve Stenosis at AHA Scientific Sessions 2025 Kardigan, a cardiovascular-focused biotechnology company working to modernize drug development for heart disease, announced encouraging new Phase 2 results for its…
CrossBridge Bio Awarded “Best Drug Developer” at the 2025 World ADC Awards, Celebrating Breakthrough Innovation in Dual-Payload ADCs CrossBridge Bio, an emerging biopharmaceutical innovator specializing in the development of next-generation dual-payload antibody-drug conjugates (ADCs), announced that it has received the…
Indapta Therapeutics Showcases Promising Clinical Activity of IDP-023 Allogeneic g-NK Cell Therapy in Relapsed/Refractory Multiple Myeloma at SITC 2025 Indapta Therapeutics, Inc., a privately held, clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer and autoimmune disease, has presented…
Northwell Study Offers Nuanced Hope for Long-Term Seizure Reduction in Chronic, Treatment-Resistant Epilepsy For millions of individuals worldwide, epilepsy remains one of the most challenging chronic neurological disorders to manage. Although many patients achieve seizure control through medication, roughly one-third…
Catalent Showcases SMARTag® ADC Pipeline Progress and New Enhanced Conjugate Class at 16th World ADC San Diego Catalent, Inc., a global leader in contract development and manufacturing services for advanced therapeutics, has unveiled a series of promising updates to its…
Serenity Mental Health Centers Expands Access to Breakthrough Ketamine Treatment in Colorado Springs Serenity Mental Health Centers, one of the nation’s fastest-growing providers of advanced psychiatric care, has announced the expansion of its ketamine treatment services in Colorado Springs. This…
Zoetis Appoints Kevin Esch as New R&D President to Succeed Rob Polzer in 2026, Marking a Strategic Leadership Transition in Global Animal Health Innovation Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, announced a major leadership transition in…
Genetix Biotherapeutics to Highlight U.S. Gene Therapy Implementation and Patient Experience Data at ASH 2025 Genetix Biotherapeutics Inc. announced that an analysis of recent patient experience data from the U.S. commercial implementation of its landmark gene therapies LYFGENIA™ and ZYNTEGLO™…
Tezspire Secures U.S. FDA Approval for Chronic Rhinosinusitis with Nasal Polyps, Expanding Its Reach Beyond Severe Asthma AstraZeneca and Amgen have announced that their jointly developed biologic, Tezspire (tezepelumab), has received U.S. Food and Drug Administration (FDA) approval for the…